Optimization of Ketobenzothiazole‐Based Type II Transmembrane Serine Protease Inhibitors to Block H1N1 Influenza Virus Replication

Abstract

AbstractHuman influenza viruses cause acute respiratory symptoms that can lead to death. Due to the emergence of antiviral drug‐resistant strains, there is an urgent requirement for novel antiviral agents and innovative therapeutic strategies. Using the peptidomimetic ketobenzothiazole protease inhibitor RQAR‐Kbt (IN‐1, aka N‐0100) as a starting point, we report how substituting P2 and P4 positions with natural and unnatural amino acids can modulate the inhibition potency toward matriptase, a prototypical type II transmembrane serine protease (TTSP) that acts as a priming protease for influenza viruses. We also introduced modifications of the peptidomimetics N‐terminal groups, leading to significant improvements (from μM to nM, 60 times more potent than IN‐1) in their ability to inhibit the replication of influenza H1N1 virus in the Calu‐3 cell line derived from human lungs. The selectivity towards other proteases has been evaluated and explained using molecular modeling with a crystal structure recently obtained by our group. By targeting host cell TTSPs as a therapeutic approach, it may be possible to overcome the high mutational rate of influenza viruses and consequently prevent potential drug resistance.